Valion Other Tuesday, July 14, 2026 +1.00 Positive

Valion Bio advances Entolimod manufacturing and oncology strategies.

The company demonstrated a 200-fold manufacturing scale-up and initiated studies for oncology supportive care. These strategic developments actively expand Valion Bio's biomanufacturing capabilities and broaden its platform beyond biodefense into cancer treatment.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day